[Future therapeutic strategies for multiple myeloma]

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma (MM) is a challenging hematological malignancy characterized by frequent relapses.
• Current treatments including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies offer limited long-term remission for relapsed and refractory multiple myeloma (RRMM).

Purpose of the Study:

• To provide an overview of recent clinical study results for novel therapies targeting B-cell maturation antigen (BCMA) in multiple myeloma.
• To discuss the potential and challenges of BCMA-targeted CAR-T cell therapy for RRMM patients.

Main Methods:

• Review of clinical study data for BCMA-targeting therapies.
• Analysis of outcomes for CAR-T cell therapy, antibody-drug conjugates, bispecific antibodies, selinexor, and venetoclax in RRMM.

Main Results:

• CAR-T cell therapy targeting BCMA demonstrates promising results, particularly for triple-class refractory MM patients.
• Emerging therapies like antibody-drug conjugates and bispecific antibodies are also being investigated.
• Despite promising results, challenges such as short progression-free survival and relapse rates persist with CAR-T cell therapy.

Conclusions:

• BCMA-targeted CAR-T cell therapy represents a potentially game-changing treatment for multiple myeloma.
• Further research and clinical advancements are necessary to overcome current limitations and achieve long-term treatment-free survival for RRMM patients.
• The availability of CAR-T cell therapy in Japan since January 2022 marks a significant step, but ongoing issues require resolution.